Segments - by Product Type (Portable Oxygen Concentrators and Stationary Oxygen Systems), by Delivery Devices (Nasal Cannulas, Oxygen Masks, Venturi Masks, Non-rebreather Masks), by Technology (Continuous Flow and Pulse Dose), by Patient Age (Pediatric and Adult)
The global Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market size was USD XX Billion in 2023 and is likely to reach USD XX Billion by 2032, expanding at a CAGR of XX% during 2024–2032. The market growth is attributed tothe increasing prevalence of COPD, primarily by smoking.
According to the WHO, COPD is projected to become the third leading cause of death worldwide by 2030. Cases of COPD are increasing daily due to the rise of risk factors such as smoking, air pollution, and occupational exposure to dust and hazardous chemicals. The surge in diagnosed cases has made oxygen therapy a cornerstone in the treatment of COPD.
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021, approximately 5% of all global deaths.
COPD patients usually develop lung damage or phlegm accumulation. The symptoms of COPD include coughing, wheezing, and exhaustion. Oxygen therapy helps people with COPD breathe better and live longer. It is a well-established treatment for patients with severe resting hypoxemia, a condition in which blood oxygen levels drop while resting.
Oxygen therapy for COPD patients is aimed at increasing the amount of oxygen in the lungs and the bloodstream. Oxygen is delivered through a nasal cannula, facemask, or a tube that runs from an oxygen tank directly into the windpipe.
Technological advancements in oxygen therapy devices are a major market driver. The development of portable oxygen concentrators, which offer mobility and convenience for patients was a major innovation in the oxygen therapy market.
R&D efforts are focused on making devices small, lightweight, and capable of delivering continuous oxygen supply. Such devices are bound to improve the quality of life of patients. Developments in sensor technology and connectivity of empowered remote monitoring and management of oxygen therapy for COPD patients.
The global aging population is driving the market. With age, respiratory ailments such as COPD become frequent. According to the UN, the global population aged 60 years and over is expected to double by 2050. Elderly individuals are susceptible to COPD, further contributing to the market growth as they generally require long-term oxygen therapy.
The rising trend of home healthcare is contributing to the market growth. People are choosing home-based care for COPD treatment. The availability of portable oxygen concentrators has provided a boost to the COPD oxygen therapy market.
Demand for oxygen therapy consumables such as nasal cannulas, oxygen tanks, facemasks, humidifiers, and pulse oximeters has surged in recent years. Manufacturers are not just focusing on the development of comfortable, long-term-use devices buton making the said devices compatible with a wide array of oxygen therapy devices as well.
The high cost of oxygen therapy is a significant market restraint. COPD is a chronic disease that requires long-term care and specialized treatment, both of which are expensive. Additionally, COPD isaccompanied by various other afflictions, increasing overall treatment costs.
This is a significant barrier, particularly for populations in Low- and Middle–income countries (LMIC). Additionally, the high costs affect healthcare providers as they struggle to cover the cost of treatment for a large number of patients.
This often leads to underdiagnosis and undertreatment, which results in restricted access to medications and medical devices at the cost of the patient’s access to sufficient healthcare.
The potential adverse effects of oxygen therapy hinder the market. Providing too much oxygen damages lung tissues, especially in patients afflicted with severe COPD. Continuous use of nasal cannulas causes dryness and irritation in the nasal passages.
Pressure points from oxygen delivery devices lead to skin irritation. Inadequate monitoring of oxygen saturation levelsleads to unnecessary oxygen use. Patients are likely to find oxygen masks or cannulas uncomfortable, leading to non-adherence to prescribed treatments. The need to carry oxygen equipment is burdensome and limiting to free mobility and activity levels for patients.
The development of innovative therapies and treatment approaches is creating new opportunities in the market. Most COPD treatments focus on managing symptoms and slowing the progression of the disease. There is a significant need for new and innovative measures to provide better patient outcomes in the face of the rising number of cases. Wearable devices and remote monitoring systems are some of the avenues opening up for research and development projects.
Further opportunities lie in developing innovative oxygen delivery systems, expanding the telemedicine integration for patient monitoring, personalized treatment plans, initiatives for patient education, and improving market access in underserved regions.
Increasing adoption of home-based oxygen therapy solutions is expected to create lucrative opportunities for market players, driven by the desire for improved quality of life, reduced hospital stay, and low healthcare costs. Portable, user-friendly oxygen concentrators are being increasingly sought after.
Home-based oxygen therapy allows patients to supervise their condition in a comfortable and familiar environment, improving their adherence to prescribed treatment and raising patient morale and satisfaction. The shift towards a patient-centric approach represents a substantial growth opportunity for manufacturers and providers of oxygen therapy devices, for the development of new innovative and user-friendly products.
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Chronic Obstructive Pulmonary Disease (COPD) Oxygen Therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2023 |
Historic Data |
2017 -2022 |
Forecast Period |
2024–2032 |
Segmentation |
Product Type (Portable Oxygen Concentrators and Stationary Oxygen Systems), Delivery Devices (Nasal Cannulas, Oxygen Masks, Venturi Masks, and Non-rebreather Masks), Technology (Continuous Flow and Pulse Dose), Patient Age (Pediatric and Adult), and End User (Hospital, Clinic, and Homecare) |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
Key Players Covered in the Report |
Abbott; Drive DeVilbiss Healthcare; F. Hoffmann-La Roche Ltd; Fisher & Paykel Healthcare; GE Healthcare; GlaxoSmithKline (GSK plc.); Invacare Holdings Corporation; Nidek Medical Products, Inc.; Philips Respironics (Koninklijke Philips N.V.); and OMRON Healthcare |
Based on product type, the Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is divided into portable oxygen concentrators and stationary oxygen systems.
The stationary oxygen systems segment holds a major market share due to the high prevalence of COPD and the need for consistent oxygen delivery at home. The segment consists of large, non-portable oxygen concentrators that are designed to be used primarily at home, providing a continuous supply of oxygen to patients who typically stay in one location within their residence. Stationary oxygen systems offer greater oxygen output capacity to meet the needs of severe COPD cases.
Devices such as liquid oxygen devices and oxygen cylinders are widely used due to their reliability and accessibility, especially in regions with limited technologies. Oxygen cylinders come in different sizes, catering to a variety of patient needs and usage scenarios. The demand for this segment remains high, particularly in emergency and hospital settings.
The portable oxygen concentrators segment is expected to expand at a significant growth rate in the coming years, owing to the high demand for portable oxygen solutions that allow COPD patients to maintain mobility and independence while receiving necessary oxygen therapy, particularly when outside of home premises.
Portable oxygen concentrators (POCs) separate nitrogen and oxygen from air in the environment, discards nitrogen, and supplies 95% pure oxygen to patients through a mask.
POCs are smaller than stationary oxygen systems, allowing patients to carry the device easily. COPD patients often require long-term oxygen therapy, and POCs enable them to participate in daily activities without being tethered to a stationary oxygen source.
On the basis of delivery devices, the Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is segregated into nasal cannulas, oxygen masks, venturi masks, and non-rebreather masks.
The nasal cannulas segment holds a large market share due to their ability to provide higher concentrations of oxygen comfortably and efficiently, especially during exacerbations of COPD. Nasal cannulas are considered one of the most prominent options for long-term oxygen therapy due to their comfort and ease of use compared to other delivery methods.
High-flow nasal cannulas allow for higher oxygen flow rates, which is crucial for managing severe COPD cases. The benefits of nasal cannulas include improved breathing, reduced fatigue, better sleep quality, and increased energy levels.
The venturi masks segment is anticipated to grow at a substantial CAGR during the forecast period, owing to their ability to deliver precise and controlled oxygen concentrations. This ability is crucial for managing COPD, where maintaining accurate oxygen saturation is vital.
There is a high demand for venturi masks as they deliver specific oxygen concentrations by mixing room air with oxygen through controlled mechanisms. Additionally, venturi masks come with color-coded attachments, allowing healthcare providers to select the appropriate oxygen concentration for each patient based on their individual needs.
In terms of technology, the global Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is segmented into continuous flow and pulse dose.The continuous flow segment dominated the market segment due to its effectiveness in managing severe COPD cases, usually achieved through portable oxygen concentrators with continuous flow technology.
Most patients with COPD require this method for optimal oxygen delivery. Continuous flow oxygen therapy is delivered through portable oxygen concentrators, allowing patients to maintain mobility while receiving the necessary oxygen. According to NIH, multiple research studies indicate that continuous flow oxygen therapy for COPD significantly improves patient quality of life, and potentially reduces mortality rates.
The pulse dose segment is projected to register a robust growth rate during the assessment years, as pulse dose systems are designed to be efficient, delivering oxygen only during the patient’s inhalation. This saves oxygen and reduces the size of portable oxygen concentrators or tanks.
Pulse dose is commonly used in patients with mild to moderate COPD who require supplemental oxygen during activity or rest, not constantly. The segment growth is driven by its cost-effectiveness, portability, technological advancements, and increasing adoption of home-based and oxygen therapy solutions.
Based on patient age, the global Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is divided into pediatric and adult. The adult segment generated a major revenue share of the market, owing to the high prevalence of COPD among older adults. Five million adults live with chronic lung disease in the US, with more than one million prescribed long-term oxygen therapy (LTOT).
LTOT involves continuous home oxygen use for significant periods (15 hours /day) to manage severe hypoxemia. Treatment options are being improved due to advancements in oxygen delivery technology, including portable oxygen concentrators which enhance patient outcomes and quality of life.
The pediatric segment is a smaller segment, bit still significant nevertheless. COPD is generally considered a disease primarily affecting adults. However, children with severe chronic lung conditions, often stemming from premature birth complications, still necessitate oxygen therapy.
Conditions such as bronchopulmonary dysplasia and cystic fibrosis are possible causes of chronic respiratory issues. Pediatric patients require specialized oxygen delivery devices and monitoring systems, designed to suit their smaller size and developmental needs. The availability of pediatric-specific solutions highlights the market’s commitment to address the needs of all COPD patients, irrespective of age.
In terms of end user, the Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is divided into hospital, clinic, and homecare. The hospital segment holds a significant market share due to the acute care needs of severe COPD cases requiring hospitalization and the advanced monitoring capabilities available in hospital facilities.
Hospital-based oxygen therapy is essential for managing acute exacerbations, ensuring that patients receive intensive care to stabilize their condition. Hospitals see a substantial number of patients requiring oxygen therapy due to the prevalence of COPD. The segment is supported by advanced medical devices and trained healthcare professionals, able to manage complex COPD cases and oxygen therapy needs.
The homecare segment is often considered the fastest-growing segment within the overall COPD oxygen therapy market due to the increasing preference for home-based care. COPD is the primary condition driving demand for homecare oxygen therapy, as many COPD patients require long-term oxygen therapy at home to manage their symptoms and improve their quality of life.
The desire for a better quality of life, reduced hospital stays, and lower healthcare costs drive the segment. Home care allows patients to manage their condition in a comfortable and familiar environment, improving adherence to treatment and overall patient satisfaction.
Clinics are an important segment in the COPD oxygen therapy market. Clinics provide outpatient surgical and diagnostic services. The segment has seen surging demand with the growing number of clinics and the ability to deliver specialized care cost-effectively. Clinics offer a convenient and efficient alternative to hospitals, catering to patients who require short-term care of follow-ups after surgical procedures.
In terms of region, the global Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
North America holds the largest share of the market due to the pervasiveness of COPD, increasing awareness about the benefits of oxygen therapy, and rapid advancements in technology. The large patient population, robust healthcare infrastructure, and research and development in respiratory healthcare technologies further augment the growth.
The Asia Pacific market is projected to grow at a significant pace in the coming years, driven by factors such as the rising prevalence of COPD due to lifestyle changes, the increasing geriatric population, and the expanding healthcare infrastructure across the region.
Countries such as China, India, and Japan are leading the market expansion, with technological advancements in oxygen delivery services and increased availability of portable oxygen concentrators.
The Chronic Obstructive Pulmonary Disease(COPD) oxygen therapy market has been segmented on the basis of
The competitive landscape of the Chronic Obstructive Pulmonary Disease (COPD) oxygen therapy market is shaped by several major players that offer a variety of products designed to meet the needs of individuals with COPD.
These players focus on innovations in oxygen delivery systems, such as portable oxygen concentrators, oxygen cylinders, liquid oxygen systems, and pulse dose therapy devices.
Market players including Philips Healthcare, Invacare Corporation, and Drive DeVilbiss Healthcare have a strong market presence with an emphasis on user-friendly and efficient devices.
They invest heavily in research and development, focusing on portability and patient comfort. Additionally, they engage in strategic partnerships and collaborations to expand their product offerings. The key players approach the market with global distribution and efficient, high-quality products in mind.